Form 4: Syndax Pharmaceuticals CEO Sells Shares to Cover Tax Obligations
SEC Form 4
Michael A. Metzger, CEO of Syndax Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On February 10, 2025, Michael A. Metzger, the CEO of Syndax Pharmaceuticals, sold 13,288 shares of common stock at a price of $15.504 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Metzger directly owns 300,121 shares of Syndax Pharmaceuticals.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction (stock sale for tax obligations) by the CEO. It's neutral to slightly positive as it indicates the vesting of restricted stock units, which is tied to performance.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company.
Stakeholder Impact
- The sale of shares could have a minor impact on shareholders due to the increased supply of shares in the market, but it is unlikely to be significant given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of stock sale transaction |
| 02/12/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.